154 related articles for article (PubMed ID: 18794615)
1. Causes of death in the era of highly active antiretroviral therapy: a retrospective analysis of a hybrid hematology-oncology and HIV practice and the Seattle/King county adult/adolescent spectrum of HIV-related diseases project.
Uhlenkott MC; Buskin SE; Kahle EM; Barash E; Aboulafia DM
Am J Med Sci; 2008 Sep; 336(3):217-23. PubMed ID: 18794615
[TBL] [Abstract][Full Text] [Related]
2. Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections.
Dronda F; Sobrino P; Hernández-Novoa B; Caro-Murillo AM; Montero M; Iribarren JA; Sanz J; Del Mar Alonso M; Labarga P; Bernal E; Moreno S;
Curr HIV Res; 2011 Jun; 9(4):229-36. PubMed ID: 21631429
[TBL] [Abstract][Full Text] [Related]
3. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Gallafent JH; Buskin SE; De Turk PB; Aboulafia DM
J Clin Oncol; 2005 Feb; 23(6):1253-60. PubMed ID: 15718323
[TBL] [Abstract][Full Text] [Related]
4. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.
Jain MK; Skiest DJ; Cloud JW; Jain CL; Burns D; Berggren RE
Clin Infect Dis; 2003 Apr; 36(8):1030-8. PubMed ID: 12684916
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Yephthomi T; Pradeep A; Saghayam S; Flanigan T; Mayer KH; Solomon S
Int J Infect Dis; 2010 Feb; 14(2):e127-31. PubMed ID: 19632872
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
7. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
8. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
9. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
10. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.
Antiretroviral Therapy Cohort Collaboration (ART-CC)
Antivir Ther; 2015; 20(1):21-8. PubMed ID: 24675571
[TBL] [Abstract][Full Text] [Related]
12. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
13. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
[TBL] [Abstract][Full Text] [Related]
14. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
Mzileni MO; Longo-Mbenza B; Chephe TJ
Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
[TBL] [Abstract][Full Text] [Related]
15. Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans.
Nurutdinova D; Chrusciel T; Zeringue A; Scherrer JF; Al-Aly Z; McDonald JR; Overton ET
AIDS; 2012 Jan; 26(2):229-34. PubMed ID: 22089375
[TBL] [Abstract][Full Text] [Related]
16. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).
Kim JH; Psevdos G; Gonzalez E; Singh S; Kilayko MC; Sharp V
Infection; 2013 Apr; 41(2):545-51. PubMed ID: 23264096
[TBL] [Abstract][Full Text] [Related]
17. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.
Bonnet F; Morlat P; Chêne G; Mercié P; Neau D; Chossat I; Decoin M; Djossou F; Beylot J; Dabis F;
HIV Med; 2002 Jul; 3(3):195-9. PubMed ID: 12139658
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
[TBL] [Abstract][Full Text] [Related]
19. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
20. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]